Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 14/20 | 0.66 |
| ▸ | PDE4A | P27815 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893728 | 0.90 | MDM2 (0.68) | MDM2DHODH | |
| SCHEMBL9893741 | 0.90 | MDM2 (0.53) | MDM2 | |
| SCHEMBL27879316 | 0.86 | MDM2 (0.63) | MDM2DHODH | |
| SCHEMBL9893719 | 0.85 | MDM2 (0.73) | MDM2 | |
| Lithium SCHEMBL9894073 | 0.85 | MDM2 (0.73) | MDM2PDE4BPDE4D | |
| SCHEMBL9894071 | 0.85 | MDM2 (0.73) | MDM2PDE4BPDE4D | |
| Acetamide SCHEMBL27862813 | 0.82 | MDM2 (0.69) | MDM2PDE4BPDE4D | |
| SCHEMBL9893654 | 0.81 | MDM2 (0.65) | MDM2 | |
| SCHEMBL9894276 | 0.80 | MDM2 (0.61) | MDM2 | |
| SCHEMBL9893723 | 0.80 | MDM2 (1.00) | MDM2PDE4BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885PDE4A 3278/4885PDE4B 3755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.